AQR Capital Management
ABUS icon

AQR Capital Management’s Arbutus Biopharma ABUS Stock Holding History

AQR Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Buy
23,819
+7,036
+42% +$30.8K ﹤0.01% 3679
2025
Q4 		$80.7K Buy
16,783
+1,550
+10% +$6.97K ﹤0.01% 3475
2025
Q3 		$69.2K Sell
15,233
-22,469
-60% -$82.5K ﹤0.01% 3400
2025
Q2 		$116K Sell
37,702
-10,468
-22% -$34.8K ﹤0.01% 3151
2025
Q1 		$168K Sell
48,170
-554
-1% -$1.85K ﹤0.01% 2923
2024
Q4 		$159K Buy
48,724
+15,006
+45% +$55.2K ﹤0.01% 2709
2024
Q3 		$130K Buy
+33,718
New +$129K ﹤0.01% 2627
2023
Q4 		– Sell
-40,598
Closed -$82.4K – 2322
2023
Q3 		$82.4K Buy
40,598
+26,075
+180% +$54.7K ﹤0.01% 2249
2023
Q2 		$33.4K Sell
14,523
-6,412
-31% -$16.7K ﹤0.01% 2170
2023
Q1 		$63.4K Sell
20,935
-1,818
-8% -$5.13K ﹤0.01% 2134
2022
Q4 		$53K Sell
22,753
-69
-0.3% -$165 ﹤0.01% 2168
2022
Q3 		$44K Buy
22,822
+3,392
+17% +$7.99K ﹤0.01% 2152
2022
Q2 		$53K Buy
+19,430
New +$49.7K ﹤0.01% 2131
2021
Q3 		– Sell
-19,036
Closed -$58K – 2236
2021
Q2 		$58K Buy
+19,036
New +$59K ﹤0.01% 2207
2019
Q2 		– Sell
-28,128
Closed -$101K – 2057
2019
Q1 		$101K Sell
28,128
-93,514
-77% -$359K ﹤0.01% 2135
2018
Q4 		$466K Buy
121,642
+75,066
+161% +$370K ﹤0.01% 1808
2018
Q3 		$440K Buy
46,576
+27,354
+142% +$272K ﹤0.01% 1991
2018
Q2 		$140K Buy
+19,222
New +$114K ﹤0.01% 2267

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

AQR Capital Management's ABUS Position: Q1 2026 in Review

AQR Capital Management increased its Arbutus Biopharma (ABUS) stake by 42% in Q1 2026, buying an estimated $30.8K and bringing the position to 23,819 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

AQR Capital Management first reported a position in ABUS in Q2 2018 and has held it in 18 quarters since. The position peaked at $466K in Q4 2018. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • AQR Capital Management held 23,819 shares of Arbutus Biopharma worth $107K as of Q1 2026.
  • AQR Capital Management bought 7,036 Arbutus Biopharma shares in Q1 2026, an estimated $30.8K.
  • Arbutus Biopharma made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3679 holding.
  • AQR Capital Management first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 18 quarters since.
  • AQR Capital Management's Arbutus Biopharma position peaked at $466K in Q4 2018.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.